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Previously, we have demonstrated that an MEF2 con-
sensus sequence located between 2473/2464 in the hu-
man GLUT4 gene was essential for both tissue-specific
and hormonal/metabolic regulation of GLUT4 expres-
sion (Thai, M. V., Guruswamy, S., Cao, K. T., Pessin, J. E.,
and Olson, A. L. (1998) J. Biol. Chem. 273, 14285–14292).
To identify the specific MEF2 isoform(s) responsible for
GLUT4 expression, we studied the pattern of expression
of the MEF2 isoforms in insulin-sensitive tissues. Both
heart and skeletal muscle were found to express the
MEF2A, MEF2C, and MEF2D isoforms but not MEF2B.
However, only the MEF2A protein was selectively down-
regulated in insulin-deficient diabetes. Co-immunopre-
cipitation with isoform-specific antibodies revealed
that, in the basal state, essentially all of the MEF2A
protein was presented as a MEF2A-MEF2D heterodimer
without any detectable MEF2A-MEF2A homodimers or
MEF2A-MEF2C and MEF2C-MEF2D heterodimers. Elec-
trophoretic mobility shift assays revealed that nuclear
extracts from diabetic animals had reduced binding to
the MEF2 binding site compared with extracts from con-
trol or insulin-treated animals. Furthermore, immu-
nodepletion of the MEF2A-MEF2D complex from control
extracts abolished binding to the MEF2 element. How-
ever, addition of MEF2A to diabetic nuclear extracts
fully restored binding activity to the MEF2 element.
These data strongly suggest that the MEF2A-MEF2D
heterodimer is selectively decreased in insulin-deficient
diabetes and is responsible for hormonally regulated
expression of the GLUT4 gene.
The major insulin-responsive facilitative glucose transporter
GLUT41 is predominantly expressed in striated muscle and
adipocytes, tissues that display insulin-stimulated glucose up-
take (1–3). In the basal state, this transporter slowly recycles
between a poorly described intracellular storage compart-
ment(s) and the plasma membrane such that the steady-state
distribution favors intracellular localization (3, 4). However,
following insulin stimulation, there is a dramatic increase in
the rate of GLUT4 exocytosis with a smaller decrease in the
rate of plasma membrane endocytosis (4). This redistribution of
pre-existing GLUT4 protein provides the major mechanism
accounting for the acute insulin-stimulated glucose uptake that
occurs in the post-prandial state (1, 3, 5, 6). In addition to this
acute regulation of GLUT4-containing vesicle trafficking, the
expression of GLUT4 is transcriptionally regulated in a variety
of persistent altered metabolic states. For example, states of
insulin deficiency induced by either streptozotocin (STZ) treat-
ment or nutritional restriction results in decreased GLUT4
mRNA and protein in adipose tissue and cardiac and skeletal
muscle (7–9). The decrease in GLUT4 protein levels directly
correlates with a decrease in GLUT4 mRNA and the rate of
GLUT4 gene transcription (10). Promoter analysis in tissue
cultured 3T3L1 adipocytes has recently identified an insulin-
responsive element (2706/2676) located in the 59-flanking re-
gion of the murine GLUT4 gene (11, 12). In addition, analysis
of tissue-specific GLUT4 gene expression in the cultured
C2C12 muscle cell line demonstrated the necessary require-
ment for a myocyte enhancer factor 2 (MEF2) cis-DNA regula-
tory element (13). The importance of the MEF2 site was further
supported by expression analysis in transgenic mice that dem-
onstrated the essential function of the human GLUT4 MEF2
site (2473/2464) in both tissue-specific and hormonal/meta-
bolic regulation (14). Importantly, in vitro MEF2 sequence-
specific binding activity was found to decrease following STZ-
induced diabetes (15).
Currently, there are four known members of the mammalian
MEF2 family termed MEF2A, MEF2B, MEF2C, and MEF2D
(16, 17). These DNA-binding proteins are important transcrip-
tion factors in both the maintenance and induction of the mus-
cle differentiated phenotype (18–21). These factors bind DNA
as homo- and heterodimers but can also form protein-protein
interactions with the thyroid hormone receptor (22), and mem-
bers of the basic helix-loop helix family of transcription factors,
such as MyoD or myogenin (18, 20, 22–25).
Although the MEF2 element appears to be essential for
GLUT4 expression, the specific MEF2 isoform(s) regulating the
tissue-specific and hormonal/metabolic regulation of the
GLUT4 gene has not been determined. In this report, we dem-
onstrate that cardiac and skeletal muscle expression of GLUT4
is dependent upon a MEF2A-MEF2D heterodimer. STZ-in-
duced insulin deficiency results in a specific decrease in expres-
sion of the MEF2A mRNA and protein. Furthermore, the ad-
dition of in vitro synthesized MEF2A protein to diabetic
nuclear extracts restored the binding activity to a comparable
level found in control or insulin-treated animals.
EXPERIMENTAL PROCEDURES
Rats—Male Sprague-Dawley rats (180–200 g) were obtained from
Harlan. These animals were either left untreated or made diabetic by
an intraperitoneal injection of STZ (90–100 mg/kg body weight) follow-
ing an overnight fast. Three days following the injection, blood tail
samples were checked for glucose concentration using a One-Touchy
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glucometer (Lifescan, Milpitas, CA). Animals with a glycemia $300
mg/dl were considered diabetic and sacrificed 3–5 days following the
STZ injection by CO2 asphyxiation for removal of tissues. A set of
diabetic animals were also treated with human insulin for 7 days with
a daily dose of 3 units of regular insulin (Humulin-R) and 2 units of
long-acting insulin (Humulin-N) as described previously (26, 27). All
tissues were snap-frozen in liquid nitrogen and kept at 280 °C until
used. All procedures were reviewed and approved by the University of
Iowa Committee for the Care and Use of Animals.
RNA Isolation and Northern Blot Analysis—RNA was extracted
with guanidinium thiocyanate method using the RNAzol reagent from
TelTest (Friendswood, TX) and following the manufacturer’s instruc-
tions. For Northern blots, 30 mg of total RNA was fractionated in a 1%
formaldehyde agarose gel. The samples were then transferred to a
Hybond-N nylon membrane (Amersham Pharmacia Biotech) overnight
and prehybridized at 65 °C for 3–4 h in a solution containing 20%
formamide, 43 SSPE, 53 Denhardt’s, 5% SDS, 10% dextran sulfate, 40
mM HCl, 0.4 mg/ml salmon sperm DNA, and 0.2 mg/ml yeast tRNA. The
same solution was used for overnight hybridization at 65 °C with 106
cpm/ml 32P-random primed labeled probe corresponding to full-length
human a-actin, rat GLUT4, human MEF2A, and mouse MEF2B,
MEF2C, and MEF2D cDNAs. The cDNA probes were labeled using
[a-32P]dCTP and the Rediprime labeling kit (Amersham Pharmacia
Biotech) following manufacturer’s directions. After hybridization mem-
branes were washed thoroughly and exposed to film overnight at
270 °C.
Preparation of Nuclear Extracts and Total Membranes—Nuclear ex-
tracts from heart and skeletal muscle were obtained as described by
Thai et al. (15) with minor modification. Briefly, frozen tissues were
pulverized in liquid nitrogen and then resuspended in homogenization
buffer A (250 mM sucrose; 10 mM Hepes, pH 7.6; 25 mM KCl; 1 mM
EDTA; 10% glycerol; 0.15 mM spermine; 0.5 mM spermidine; 0.1 mM
PMSF; 2 mg/ml each aprotinin, leupeptin, and pepstatin A; and 6 mg/ml
each TLCK and TPCK. The tissues were homogenized with 10 strokes
of a Teflon pestle and filtrated through gauze and centrifuged at
3,900 3 g for 10 min at 4 °C. The supernatant was then centrifuged at
200,000 3 g for 1 h at 4 °C to obtain a pellet of crude total membranes.
The pellet from the low speed centrifugation was resuspended in 10 ml
of homogenization buffer A and homogenized in a loose-type Dounce
homogenizer. The homogenate was then layered over 0.5 volume of
buffer B (1 M sucrose; 10 mM Hepes, pH 7.6; 25 mM KCl; 1 mM EDTA;
10% glycerol; 0.15 mM spermine; 0.5 mM spermidine; 0.1 mM PMSF; 2
mg/ml each aprotinin, leupeptin, and pepstatin A; and 6 mg/ml each
TLCK and TPCK, followed by centrifugation at 3,900 3 g for 10 min at
4 °C. The pellet was then resuspended in buffer A/glycerol (9:1, w/w)
and layered over one-third buffer B:glycerol (9:1). The gradient was
centrifuged at 48,000 3 g for 30 min at 4 °C. The semi-purified nuclear
pellet was resuspended in 1 volume of nuclear extraction buffer (10 mM
Hepes, pH 7.6, 400 mM KCl, 3 mM MgCl2, 0.1 mM EDTA, 10% glycerol,
1 mM dithiothreitol). Nuclear proteins were extracted at 4 °C for 30 min
and insoluble nuclei precipitated by centrifugation at 13,000 rpm in a
microcentrifuge for 15 min. Supernatant was dialyzed against a buffer
containing 25 mM Hepes, pH 7.5; 100 mM KCl; 0.1 mM EDTA; 10%
glycerol; 1 mM dithiothreitol; 0.1 mM PMSF; 2 mg/ml pepstatin, aproti-
nin, and leupeptin; and 6 mg/ml each of TLCK and TPCK for 2–3 h at
4 °C. The extracts were quantified for protein content using BCA
method (Pierce) and frozen in small aliquots at 270 °C.
Western Blot Analysis—Nuclear extracts (30–50 mg) were resolved in
a 10% SDS-polyacrylamide gel electrophoresis. The fractionated pro-
teins were transferred to nitrocellulose membranes in a buffer contain-
ing 25 mM Tris, 190 mM glycine, pH 8.5, at 0.6 A for 6 h at 4 °C. Filters
were then blotted for 60 min with 5% nonfat dry milk in Tris-buffered
saline/Tween buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 0.2% Tween
20). The nitrocellulose membranes were then probed with a 1:2000
dilution of MEF2A/C or a MEF2D polyclonal antibodies (kindly pro-
vided by Dr. Ron Prywes, Columbia University, New York, NY) or a
polyclonal GLUT4-specific antibody generated in our laboratory. In
addition, we have prepared a polyclonal MEF2A-specific antibody (IA-
17) generated against amino acid residues 88–131 of MEF2A and a
polyclonal MEF2C-specific antibody (IA-14) generated against amino
acid residues 311–351 of MEF2C. The filters were then washed three
times with Tris-buffered saline/Tween buffer at room temperature for
10 min and probed for 1 h at room temperature with a goat anti-rabbit
horseradish peroxidase-conjugated antibody (Pierce). Membranes were
then washed as before and proteins visualized by enhanced chemilumi-
nescence (Pierce).
In Vitro Translation of MEF2—In vitro transcription and translation
was performed using a TNT reticulocyte lysate system from Promega
(Madison, WI) following manufacturer’s instructions. For each reaction
1 mg of template DNA corresponding to full-length cDNA of MEF2A,
MEF2B, MEF2C, or MEF2D was used.
Immunoprecipitation—Nuclear extracts (50–100 mg) were incubated
with 5 mg of MEF2D monoclonal antibody (Transduction Laboratories,
San Diego, CA) coupled to goat anti-mouse IgG-agarose beads (Sigma)
in 25 mM Hepes, pH 7.6; 100 mM KCl; 0.1 mM EDTA; 10% glycerol; 1%
Nonidet P-40; 1 mM sodium vanadate; 1 mM PMSF; 2 mg/ml of pepsta-
tin, aprotinin, and leupeptin; and 6 mg/ml each of TLCK and TPCK.
Samples were microcentrifuged for 1 min and the pellets washed five
times in the above buffer. The samples were then resuspended in
Laemli sample buffer, heated for 5 min at 100 °C, and subjected to
SDS-polyacrylamide gel electrophoresis and Western blot analysis. For
immunoprecipitation with the MEF2A antibody, 2 ml of the polyclonal
IA-17 antibody were cross-linked to protein A beads with dimethyl
pimelimidate reagent using the Immunopure protein A IgG kit (Pierce).
Immunoprecipitation was then performed at 4 °C as described for the
MEF2D antibody above.
Electrophoretic Mobility Shift Assays—For electrophoretic mobility
shift assays, we used a Gelshift kit obtained from Geneka Biotechnology
(Montreal, Canada). For each reaction, 4–10 mg of nuclear extracts
were incubated in DNA binding buffer at 4 °C for 20 min and subse-
quently with the labeled oligonucleotide probe corresponding to the
MEF2 consensus binding site (Santa Cruz Biotechnology, Santa Cruz,
CA) for an additional 20 min at 4 °C. The samples were then run in a 5%
acrylamide:bisacrylamide gel (38:2) in TGE buffer (250 mM Tris, 1.9 M
glycine, and 10.5 mM EDTA). Labeling of the oligonucleotide probes was
performed as described by Ausubel et al. (28). For immunodepletion
experiments, 50–80 mg of nuclear extract were immunoprecipitated as
described above using the immunoprecipitation buffer without
detergent.
RESULTS
Insulin-deficient Diabetes Results in a Selective Decrease in
MEF2A Protein Expression in Cardiac and Skeletal Muscle—
Previously, we have demonstrated that the MEF2 consensus
cis-DNA element is essential for both tissue-specific and hor-
monal/metabolic regulation of the GLUT4 gene (15). In addi-
tion, nuclear extracts from STZ-induced diabetes bind poorly to
this element compared with control tissue extracts. In order to
identify the specific MEF2 isoform(s) responsible for the loss of
MEF2 binding and GLUT4 transcriptional activity, we initially
performed Northern blot analysis of total RNA isolated from
control, STZ-induced diabetic, and STZ-diabetic animals
treated with insulin for 1 week (Fig. 1). As typically observed,
STZ-induced diabetes resulted in decreased GLUT4 mRNA
levels in both the heart and hindlimb skeletal muscle. The
reduction in GLUT4 mRNA was fully reversible following in-
sulin treatment and was specific as there was no significant
change in a-actin expression. Similarly, the two MEF2D tran-
scripts were also unaffected in STZ-induced diabetes, whether
or not the animals were treated with insulin. In contrast,
insulin deficiency resulted in decreased levels of the MEF2A
and MEF2C mRNA that were also recovered following insulin
therapy. As expected, we were unable to detect the presence of
any MEF2B transcripts in adult striated muscles consistent
with this isoform only expressed at significant amounts during
embryonic development (29, 30) (data not shown).
Since previous studies have observed that the relative levels
of the MEF2 transcripts do not always correlate with protein
expression (31, 32), it was necessary to perform specific West-
ern blots of nuclear extracts. However, due to the high degree
of sequence identity between the MEF2 proteins, antibodies
selective for the MEF2A and MEF2C isoforms have not been
available. Therefore, to distinguish between the MEF2A and
MEF2C proteins, we generated specific polyclonal antibodies
as described under “Experimental Procedures.” To demon-
strate the specificity of several MEF2 antibodies, we in vitro
translated the three MEF2 isoforms (MEF2A, MEF2C, and
MEF2D), followed by immunoblotting (Fig. 2). In the absence of
any template, none of the antibodies detected any immunore-
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active protein. As reported previously (33), an antibody pre-
pared against MEF2A kindly provided by Dr. Ron Prywes
cross-reacted with both the MEF2A and MEF2C isoforms but
did not detect MEF2D (Fig. 2A). In contrast, the IA-17 antibody
was specific for MEF2A, whereas the IA-14 was specific for
MEF2C (Fig. 2, B and C). Furthermore, the two MEF2D anti-
bodies (one polyclonal kindly provided by Dr. Ron Prywes, and
one monoclonal from Signal Transduction Laboratories) were
both specific for MEF2D and did not cross-react with either
MEF2A or MEF2C (Fig. 2, D and E). In addition, although the
IA-17 MEF2A antibody was capable of immunoprecipitating
the native protein, the IA-14 MEF2C was only able to react in
Western blots and was incapable of immunoprecipitating the
native MEF2C protein (see Fig. 5 and data not shown).
In any case, having established the specificity of these anti-
bodies, we next assessed the expression of the MEF2 isoforms
in cardiac and skeletal muscle nuclear extracts from control,
diabetic, and insulin-treated diabetic animals (Fig. 3). Immu-
noblotting with the MEF2A/C antibody demonstrated that one
and/or both of these isoforms was decreased in streptozotocin-
induced diabetes. The decrease in MEF2A/C immunoreactivity
was specifically due to a loss of MEF2A protein without any
effect on the MEF2C protein as detected by the IA-17 and IA-14
antibodies. Furthermore, the diabetic state had no effect on
MEF2D protein levels. The changes in MEF2A protein levels
directly correlated with the changes in GLUT4 protein. To-
gether, these data suggest that the expression of the MEF2A
nuclear protein isoform is selectively down-regulated in insu-
lin-deficient diabetes.
MEF2A Is Specifically Complexed with MEF2D—The MEF2
family of transcription factors bind to DNA as either ho-
modimeric or heterodimeric complexes (16). To examine the
association state of MEF2A, we initially immunoprecipated
nuclear extracts with the specific MEF2D antibody and deter-
mined the amount of co-immunoprecipitated MEF2 isoforms
(Fig. 4). In the absence of the MEF2D antibody, all the MEF2A,
MEF2C, and MEF2D proteins remained in the supernatant
without any protein detected in the immunoprecipitated pel-
lets. In contrast, incubation with the MEF2D antibody resulted
in the quantitative depletion of the MEF2D protein from the
supernatant and appearance in the immunoprecipitated pellet.
Western blots of the MEF2D immunoprecipitates demon-
strated that all the MEF2A isoform was co-immunoprecipi-
tated with MEF2D, whereas there was essentially no co-immu-
noprecipitated MEF2C protein, which was completely retained
in the supernatant.
To further confirm the specific interaction of MEF2A with
MEF2D, nuclear extracts were immunoprecipitated with the
MEF2A-specific antibody (Fig. 5). Under these conditions, the
MEF2A protein was completely immunodepleted from the cell
extracts. This resulted in the co-immunoprecipitation of ap-
proximately 33% of the MEF2D protein, as observed both by its
depletion from the supernatant and appearance in the immu-
noprecipitated pellet. Furthermore, essentially none of the
MEF2C protein was immunodepleted from the supernatant
following MEF2A immunoprecipitation. Although we were un-
able to immunoblot the MEF2A immunoprecipitates with the
MEF2C antibody due to heavy chain cross-reactivity, these
data are consistent with the absence of a MEF2A-MEF2C
complex. It should also be noted that, since the MEF2C anti-
body (IA-14) was unable to immunoprecipitate the native
MEF2C protein, we could not examine the co-immunoprecipi-
FIG. 1. MEF2A, MEF2C, and GLUT4 mRNA levels are de-
creased in striated muscle of insulin-deficient diabetic rats.
Total heart (A) and hindlimb skeletal muscle (B) RNA (30 mg) was
isolated from control (C), STZ-diabetic (D), and insulin-treated STZ-
diabetic rats (I). The RNA was resolved in an agarose denaturing gel,
transferred to a nylon membrane, and probed with full-length 32P-
labeled cDNAs corresponding to MEF2A, MEF2C, MEF2D, GLUT4, or
a-actin genes as described under “Experimental Procedures.” This is a
representative experiment independently performed two times.
FIG. 2. Western blot analysis of in vitro transcribed and trans-
lated MEF2 isoforms. The empty vector (2), MEF2A (A), MEF2C (C),
and MEF2D (D) cDNAs were in vitro translated and resolved by 10%
SDS-polyacrylamide gel electrophoresis. The samples were then trans-
ferred to a nitrocellulose membrane and immunoblotted with the
MEF2A polyclonal antibody provided by Dr. Ron Prywes (A), the
MEF2A IA-17 polyclonal antibody (B), the MEF2C IA-14 polyclonal
antibody (C), the MEF2D polyclonal antibody obtained from Dr. Ron
Prywes (D), and the MEF2D monoclonal antibody obtained from Signal
Transduction Laboratories (E) as described under “Experimental Pro-
cedures.” This is a representative experiment independently performed
two times.
FIG. 3. MEF2A protein is specifically decreased in striated
muscle of insulin-deficient diabetic rats. Nuclear extracts were
isolated from the heart (A) and hindlimb skeletal muscles (B) of control
(C), STZ-diabetic (D), and insulin-treated STZ-diabetic (I) rats. The
protein samples (30 mg) were resolved by 10% SDS-polyacrylamide gel
electrophoresis and transferred to a nitrocellulose membrane. The
membranes were then immunoblotted with the MEF2A polyclonal an-
tibody provided by Dr. Ron Prywes, the MEF2A IA-17 polyclonal anti-
body, the MEF2C IA-14 polyclonal antibody, and the MEF2D mono-
clonal antibody obtained from Signal Transduction Laboratories as
described under “Experimental Procedures.” This is a representative
experiment independently performed three times.
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tation of MEF2C with MEF2A or MEF2D. Nevertheless, these
data indicate that the majority of the MEF2A protein existing
as a heterodimeric complex with MEF2D, whereas MEF2D is
found in both a heterodimeric complex with MEF2A and as a
MEF2D-MEF2D homodimeric complex. Importantly, MEF2C
is apparently not complexed with either MEF2A or MEF2D
and therefore must necessarily be present as a homodimeric
MEF2C-MEF2C complex, or perhaps complexed to another
transcription factor.
The MEF2A-MEF2D Heterodimeric Complex Interacts with
the GLUT4 MEF2-responsive Element—To assess the func-
tional binding properties of the MEF2 dimeric complexes from
heart nuclear extracts, we next examined MEF2 DNA binding
by electrophoretic mobility shift assays (Fig. 6). Using a con-
sensus MEF2 double-stranded oligonucleotide, we observed
that heart nuclear extracts resulted in a specific decrease in the
mobility of the labeled probe. In agreement with previous find-
ings (15), the MEF2-DNA complexed band was substantially
reduced in extracts isolated from diabetic animals compared
with controls rats but which fully recovered following insulin
treatment (Fig. 6A). This binding activity was specifically
blocked in the presence of either the myosin creatine kinase or
GLUT4 unlabeled MEF2 element but not by a mutant MEF2
oligonucleotide with two substitutions (C 3 G and A 3 C), in
the consensus core sequence (mutant oligonucleotide sequence:
59-GATCGCTGTAAACATAACCCTGTCG-39), that impair
MEF2 binding (15). Furthermore, the MEF2 sequence-depend-
ent binding activity was completely lost when the nuclear ex-
tracts were immunodepleted with either the MEF2D- or
MEF2A-specific antibody (Fig. 6, B and C). These data indicate
that the heterodimer MEF2A-MEF2D interacts with the
MEF2-responsive element.
Addition of MEF2A to Nuclear Extracts from Diabetic Ani-
mals Restores Binding Activity to the MEF2 Site—Since nu-
clear extracts from diabetic animals have reduced levels of
MEF2A but have normal amounts of MEF2D, re-addition of
MEF2A protein should restore binding activity to this site. To
this end, we prepared different dilutions of in vitro translated
MEF2A protein and compared these to the endogenous MEF2A
protein present in control extracts (Fig. 7A). The amount of in
vitro translated MEF2A protein present in 0.15–0.3 ml of tran-
scription reaction was found to be similar to the endogenous
FIG. 4. Immunoprecipitation of MEF2D results in the co-pre-
cipitation of MEF2A in striated muscle nuclear extracts. Heart
(A) and hindlimb skeletal muscle (B) were obtained from control rats.
The nuclear extracts (50 mg) were immunoprecipitated with the
MEF2D monoclonal antibody, and the resultant pellets and superna-
tants (SN) were subjected to 10% SDS-polyacrylamide gel electrophore-
sis and transferred to a nitrocellulose membrane. The membranes were
then immunoblotted with the MEF2D polyclonal antibody the MEF2A
IA-17 polyclonal antibody, the MEF2A polyclonal antibody (MEF2A/C)
and the MEF2C IA-14 polyclonal antibody as described under “Exper-
imental Procedures.” This is a representative experiment independ-
ently performed three times for each tissue.
FIG. 5. Immunoprecipitation of MEF2A results in the partial
co-precipitation of MEF2D in heart nuclear extracts. Heart nu-
clear extracts (50 mg) were immunoprecipitated with the MEF2A IA-17
polyclonal antibody linked to protein A beads as described under “Ex-
perimental Procedures.” Equal volumes of samples were resolved by
10% SDS-polyacrylamide gel electrophoresis and transferred to a nitro-
cellulose membranes. A, the resulting supernatant (SN) was immuno-
blotted with the MEF2A IA-17 antibody. B, the resulting supernatant
(SN) and pellet were immunoblotted with the MEF2D monoclonal an-
tibody. C, the resulting supernatant (SN) was immunoblotted with the
MEF2C IA-14 polyclonal antibody as described under “Experimental
Procedures.” This is a representative experiment independently per-
formed two times.
FIG. 6. Insulin-deficient diabetes results in a decrease DNA
binding activity to the MEF2 consensus site. A, heart nuclear
extracts (10 mg) from control (C), STZ-diabetic (D), or insulin-treated
STZ-diabetic (I) rats were incubated with a 32P-labeled 25-base pair
MEF2 consensus double-stranded oligonucleotide as described under
“Experimental Procedures.” Specific binding was determined by elec-
trophoretic mobility shift assay in the absence or presence of a 100-fold
molar excess of unlabeled muscle creatine kinase (1MEF2) oligonucleo-
tide, a 18-base pair oligonucleotide corresponding to the MEF2 site in
the GLUT4 gene (1GLUT4), or a mutated MEF2 oligonucleotide. B, the
heart nuclear extracts were first immunodepleted with the MEF2D
monoclonal antibody and equal volumes of supernatants were subjected
to electrophoretic mobility shift assays in the absence and presence of
100-fold excess cold competitor oligonucleotide. C, the heart nuclear
extracts were first immunodepleted with the MEF2A IA-17 polyclonal
antibody and equal volumes of the resultant supernatants were sub-
jected to electrophoretic mobility shift assays in the absence and pres-
ence of 100-fold excess cold competitor oligonucleotide. This is a repre-
sentative experiment independently performed two times for each
antibody.
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level of MEF2A in 30 mg of control nuclear extracts. The same
dilutions were proportionally added to nuclear extracts from
diabetic animals and tested for binding activity to the MEF2
site (Fig. 7B). The addition of similar amounts of MEF2A to the
diabetic nuclear extracts restored binding up to a level compa-
rable to that observed in the control extract. In fact, further
addition of excess MEF2A resulted in increased binding, prob-
ably due to both MEF2A-MEF2D complex formation and the
presence of MEF2A-MEF2A homodimers. Taken together,
these data demonstrate that the MEF2A-MEF2D complex is
responsible for binding to the GLUT4 MEF2 site and that the
down-regulation of MEF2A protein levels in insulin-deficient
diabetes accounts for the lack of GLUT4 gene expression in
striated muscle.
DISCUSSION
It has been well established that insulin stimulates the re-
cruitment or translocation of pre-formed GLUT4 glucose trans-
porter proteins from intracellular storage sites to the cell sur-
face membrane (1–3, 5).This process is necessary for normal
tissue (striated muscle and adipose) insulin sensitivity and the
maintenance of whole body glucose homeostasis. However, in
addition to the acute stimulation of GLUT4 protein intracellu-
lar trafficking, the tissue-specific expression levels of GLUT4
are also regulated by a variety of hormonal/nutritional/meta-
bolic states. For example, GLUT4 expression is markedly up-
regulated during muscle and adipose differentiation and fol-
lowing muscle exercise/contraction (34–36). In contrast, states
of relative insulin deficiency (type I diabetes and fasting) result
in decreased GLUT4 expression (7, 26). Furthermore, although
there was no effect on muscle GLUT4 levels in patients with
non-insulin-dependent diabetes, there was a selective loss of
GLUT4 protein in adipose tissue (37).
Based upon these data, we and others have begun to identify
the cis-regulatory elements that are necessary for the tissue-
specific and regulated expression of the GLUT4 gene. Recently,
we have identified a consensus MEF2 binding sequence located
at (2473/2464) in the human GLUT4 gene (13, 15). Deletions
or point mutations within this element completely prevented
tissue-specific and hormonally/metabolically regulated expres-
sion in both differentiating culture muscle C2C12 cells and
more importantly in transgenic mice (15). Furthermore, DNA
binding activity to this sequence was markedly reduced in
nuclear extracts from insulin-deficient diabetic rats but was
fully restored following insulin therapy. Thus, these data pro-
vide compelling evidence that the MEF2 binding site is, at
least, one essential functional element in the expression of the
GLUT4 gene.
There are four known members of the mammalian MEF2
family of transcription factor, and since MEF2B expression is
restricted to early embryo development (29, 30), the other
MEF2 isoforms were likely candidates responsible for the loss
of DNA binding activity in nuclear extracts from diabetic ani-
mals. To this end, Western blotting using isoform-specific an-
tibodies demonstrated that only the level of MEF2A protein
was down-regulated in both skeletal muscle and heart of insu-
lin-deficient diabetic rats. Interestingly, the mRNA of MEF2C
was also decreased; however, this did not result in any signif-
icant change in protein expression. Previous studies have also
observed a discordance in the levels of MEF2 mRNA versus
protein, suggesting the presence of post-transcriptional control
mechanism(s) (31, 32). In any case, the decrease in MEF2A
expression correlated with the decrease in GLUT4 gene expres-
sion and reduction in nuclear extract binding activity to the
MEF2 consensus sequence. These findings were confirmed by
the addition of in vitro translated MEF2A protein to diabetic
nuclear extracts, which at the appropriate endogenous amount
restored the DNA binding activity to the same level as found in
control nuclear extracts.
At present, the mechanism(s) regulating MEF2 gene expres-
sion and protein levels remains largely unknown. All the MEF2
genes contain large 59-noncoding regions with multiple spliced
exons and large introns. In Drosophila, two D-MEF enhancers
have been described, one that binds the cardiac homeodomain
protein Tinman (38) and another controlled by the basic helix-
loop helix transcription factor Twist (39). However, no cis-
regulatory sequences have yet been described for any verte-
brate MEF2 gene. Alternatively, MEF2A and also MEF2C can
be transcriptionally activated by phosphorylation through the
p38 mitogen-activated protein kinase (40–43) and protein ki-
nase C isoforms (41). In addition, MEF2C has been reported to
undergo nuclear export into the cytoplasm following transform-
ing growth factor-b stimulation (44).
Although we cannot exclude these possibilities for the loss of
MEF2A expression in muscles of insulin-deficient diabetic rats,
an additional mechanism may be envisaged based upon the
dimerization of the MEF2 isoforms. In this study, we have also
observed that the MEF2A antibody will co-immunoprecipitate
approximately one-third of the MEF2D protein, whereas the
MEF2D antibody will co-immunoprecipitate essentially all of
the MEF2A protein. These data suggest that all the MEF2A
protein exists as an MEF2A-MEF2D heterodimer. Since
MEF2C is not co-immunoprecipitated with MEF2D, these data
FIG. 7. Addition of in vitro translated MEF2A protein restores
DNA binding activity in nuclear extracts from diabetic rats. A,
control heart nuclear extracts from (30 mg) and increasing amounts of in
vitro translated MEF2A protein (0.003, 0.03, 0.06, 0.15, 0.3, 0.6, 1.5,
and 3 ml of the reaction) were subjected to Western blotting as described
under “Experimental Procedures.” B, nuclear extracts (10 mg) obtained
from control (C), STZ-diabetic (D), and insulin-treated STZ-diabetic
rats (I) were subjected to electrophoretic mobility shift assay using the
32P-labeled 25-base pair MEF2 consensus double-stranded oligonucleo-
tide in the absence or presence of 100-fold excess unlabeled competitor
oligonucleotide. The diabetic extracts (10 mg) were also pre-mixed with
increasing amounts of in vitro translated MEF2A (0.001, 0.01, 0.02,
0.05, 0.1, 0.2, 0.5, and 1 ml of the reaction), in the same proportion of the
samples used for Western blot in panel A. This is a representative
experiment independently performed two times.
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further indicate that the excess MEF2D is present in an
MEF2D-MEF2D homodimer. The presence of an MEF2A-
MEF2D heterodimer is consistent with studies in the HeLa cell
system but is somewhat in disagreement with cultured C2C12
cells (45). In any case, decreased MEF2A expression would
therefore increase the relative proportion of MEF2D-MEF2D
homodimers. Although it has been suggested that MEF2D ho-
modimers can function as a transcriptional inhibitor (45), we do
not feel that this is likely for the GLUT4 promoter. The fact
that decreased levels of MEF2A, either in diabetic nuclear
extracts or by MEF2A antibody immunodepletion, markedly
reduces DNA binding strongly suggests the MEF2D ho-
modimer has a relatively low affinity for the GLUT4 MEF2
element.
In summary, our data demonstrate that MEF2A protein
levels are selectively reduced in striated muscle of insulin-
deficient diabetic rats. This loss of MEF2A expression accounts
for the reduction in DNA binding activity and directly corre-
lates with the decrease in GLUT4 gene expression. Future
studies are now needed to determine whether the down-regu-
lation of MEF2A expression occurs at the transcriptional or
post-transcriptional level. In addition, further analysis will be
necessary to determine the specific functional roles of the
MEF2A-MEF2D heterodimer and MEF2D-MEF2D homodimer
in the control of GLUT4 transcriptional activity.
Acknowledgment—We thank Dr. Ron Prywes for kindly providing
the MEF2A/C and MEF2D antibodies.
REFERENCES
1. Pessin, J. E., Thurmond, D. C., Elmendorf, J. S., Coker, K. J., and Okada, S.
(1999) J. Biol. Chem. 274, 2593–2596
2. Martin, S., Slot, J., and James, D. (1999) Cell Biochem. Biophys. 30, 89–113
3. Kandror, K. V., and Pilch, P. F. (1996) Am. J. Physiol. 271, E1–E14
4. Holman, G. D., Lo Leggio, L., and Cushman, S. W. (1994) J. Biol. Chem. 269,
17516–17524
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